Table 1.

Selected clinical trials for eligibility from clinicaltrials.gov

Trials	Azacitadine alone NCT00422890	Cellular adoptive immunotherapy NCT00107354	Decitabine plus second SCT NCT00002832	DLI plus Dendritic Cells NCT00476177	Azacitadine plus DLI NCT00795548
Inclusion Criteria	Age>18 Chimerism <80% without hematologic relapse (<5% BM blasts)	Age>14 KPS 60–100% MRD	Age<60 ECOG PS 0–2 Relapsed within 12 months	Age≥18 ECOG PS 0–2 >2months since HSCT	Age>18 ECOG PS 0–2 Eligible for DLI
Exclusion Criteria	Uncontrolled infection Active HBV or HIV AST or ALT >3× normal CrCl<50ml/min WBC <3,000 Platelets <75,000	aGVHD grade III or IV cGVHD	Uncontrolled infection aGVHD grade >2 Any cGVHD Cr >2mg/dl Bilirubin >3mg/dl EF <40% CNS disease	Uncontrolled infection aGVHD grade II–IV Extensive cGVHD Prior DLI within 8 weeks On IS for <2 weeks prior to enrollment	Uncontrolled infection Active HBV or HCV Bilirubin > 1.5 xULN GFR <50ml/min Childs Pugh B or C Severe CV disease CNS disease Treatment with other investigational agents after relapse

KPS – Karnofsky performance status. ECOG PS – Eastern Cooperative Group Performance Status. HSCT – Hematopoietic Stem Cell Transplant. DLI – Donor Lymphocyte Infusion. GVHD – graft versus host disease. Cr – Creatinine. CrCl – Creatinine Clearance. EF – Ejection Fraction. CNS – central nervous system. IS – Immuno suppressions.